Insider Transactions in Q1 2022 at Deciphera Pharmaceuticals, Inc. (DCPH)
Insider Transaction List (Q1 2022)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Mar 21
2022
|
Steven L. Hoerter President and CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
3,150
-7.74%
|
$28,350
$9.11 P/Share
|
|
Feb 16
2022
|
Jama Pitman SVP, Chief Development Officer |
SELL
Open market or private sale
|
Direct |
1,146
-2.93%
|
$10,314
$9.05 P/Share
|
|
Feb 16
2022
|
Thomas Patrick Kelly Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
1,368
-2.78%
|
$12,312
$9.05 P/Share
|
|
Feb 16
2022
|
Matthew L Sherman EVP & Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
984
-1.27%
|
$8,856
$9.05 P/Share
|
|
Feb 16
2022
|
Daniel C. Martin Chief Commercial Officer |
SELL
Open market or private sale
|
Direct |
1,146
-2.3%
|
$10,314
$9.05 P/Share
|
|
Feb 16
2022
|
Daniel Lee Flynn Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
1,366
-2.77%
|
$12,294
$9.05 P/Share
|
|
Jan 18
2022
|
Daniel Lee Flynn Chief Scientific Officer |
BUY
Grant, award, or other acquisition
|
Direct |
20,500
+29.4%
|
-
|
|
Jan 18
2022
|
Jama Pitman SVP, Chief Development Officer |
BUY
Grant, award, or other acquisition
|
Direct |
13,667
+25.9%
|
-
|
|
Jan 18
2022
|
Matthew L Sherman EVP & Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
20,500
+20.86%
|
-
|
|
Jan 18
2022
|
Daniel C. Martin Chief Commercial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
13,667
+21.53%
|
-
|
|
Jan 18
2022
|
Thomas Patrick Kelly Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
20,500
+29.41%
|
-
|